奥英妥珠单抗治疗儿童复发/难治性急性淋巴细胞白血病
该研究报道了51例复发/难治性急性淋巴细胞白血病(ALL)患儿在同情用药项目中接受奥英妥珠单抗(InO)治疗的情况。在明显骨髓病变的患儿中,完全缓解率为67%,其中71%的缓解者微小残留病阴性。6例(12%)出现3级肝转氨酶升高或高胆红素血症,11例(22%)出现3/4级感染;InO治疗期间无患者发生窦状隙阻塞综合征(SOS),但后续接受造血干细胞移植的21例中有11例(52%)发生SOS。作者结论为InO耐受性好且有效,需开展前瞻性研究。
要点
- 明显骨髓病变患儿完全缓解率67%,71%的缓解者微小残留病阴性。
- InO治疗期间无SOS发生,但后续HSCT者中52%(11/21)发生SOS。
- 3例InO后复发患者检出CD22表面表达下调,可能为逃逸机制。
核心结论
- 作者认为InO是儿童复发ALL耐受性好且有效的治疗,需开展前瞻性研究。
- 作者指出,InO后接受HSCT者发生SOS的危险因素识别及降低风险的策略正在研究中。
研究设计与样本
- 回顾性报告51例在同情用药项目中接受奥英妥珠单抗治疗的复发/难治性急性淋巴细胞白血病患儿。
- 该队列为既往接受大量治疗的人群。
主要发现
- 明显骨髓病变患者中67%达到完全缓解,71%的缓解者微小残留病阴性。
- 缓解与细胞遗传学亚型、既往治疗方案的数量或类型无关。
- 3级肝转氨酶升高或高胆红素血症见于6例(12%),3/4级感染见于11例(22%)。
- InO治疗期间无患者发生窦状隙阻塞综合征;InO后接受造血干细胞移植的21例中11例(52%)发生SOS。
- 3例InO后再次复发患者检出CD22表面表达下调,为可能的逃逸机制。
局限性
- 原文结论指出需开展前瞻性研究;原文提及识别HSCT后发生SOS的危险因素及降低风险的策略正在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%) patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted. Identification of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.
引用
- Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2018. PMID: 30267011. doi:10.1038/s41375-018-0265-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。